Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study

Authors: Cull, Gavin, Burger, Jan A., Opat, Stephen, Gottlieb, David, Verner, Emma, Trotman, Judith, Marlton, Paula, Munoz, Javier, Johnston, Patrick, Simpson, David, Stern, Jennifer C., Prathikanti, Radha, Wu, Kenneth, Novotny, William, Huang, Jane, Tam, Constantine S.

Source: British journal of haematology. 196(5):1209-1218

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100142022931.0x000001&indx=1&recIds=ETOCvdc_100142022931.0x000001

Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Authors: Tam, Constantine S. ^*, Quach, Hang, Nicol, Andrew, Badoux, Xavier, Rose, Hannah, Prince, H. Miles, Leahy, Michael F., Eek, Richard, Wickham, Nicholas, Patil, Sushrut S., Huang, Jane, Prathikanti, Radha, Cohen, Aileen, Elstrom, Rebecca, Reed, William, Schneider, Jingjing, Flinn, Ian W.

Source: In Blood Advances 13 October 2020 4(19):4802-4811

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Authors: Garcia-Sanz, Ramon, Owen, Roger, Jurczak, Wojciech, Dimopoulos, Meletios A., McCarthy, Helen, Cull, Gavin, Opat, Stephen, Castillo, Jorge J., Kersten, Marie José, Wahlin, Björn E., Grosicki, Sebastian, Prathikanti, Radha, Tian, Tian, Allewelt, Heather, Cohen, Aileen Cleary, Tam, Constantine S.

Source: In Blood 2 November 2023 142 Supplement 1:3043-3043

Darbepoetin Alfa Administration to Achieve and Maintain Target Hemoglobin Levels for 1 Year in Patients With Chronic Kidney Disease

Authors: Hertel, Joachim E.W., Locay, Harold R., Scarlata, Debra S., Prathikanti, Radha, Audhya, Paul K.

Source: In Mayo Clinic Proceedings 2006 81(9):1188-1194

This result is not displayed to guests.
Login for full access.

Darbepoetin alfa Administered Every Other Week Maintains Hemoglobin Levels over 52 Weeks in Patients with Chronic Kidney Disease Converting from Once-Weekly Recombinant Human Erythropoietin: Results from Simplify the Treatment of Anemia with Aranesp (STAAR)

Authors: Hertel, Joachim, Locay, Harold, Scarlata, Debra, Jackson, Lynnae, Prathikanti, Radha, Audhya, Paul

Source: American Journal of Nephrology; 2006, Vol. 26 Issue 2, p149-156, 8p, 7 Charts, 2 Graphs

Subject Terms: KIDNEY diseases, CHRONIC kidney failure, ANEMIA, HEMOGLOBIN polymorphisms, ERYTHROPOIETIN, CARRIER proteins

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.